[go: up one dir, main page]

CA2359633A1 - Conjugues pro-apoptotiques de domiciliation et leurs methodes d'utilisation - Google Patents

Conjugues pro-apoptotiques de domiciliation et leurs methodes d'utilisation Download PDF

Info

Publication number
CA2359633A1
CA2359633A1 CA002359633A CA2359633A CA2359633A1 CA 2359633 A1 CA2359633 A1 CA 2359633A1 CA 002359633 A CA002359633 A CA 002359633A CA 2359633 A CA2359633 A CA 2359633A CA 2359633 A1 CA2359633 A1 CA 2359633A1
Authority
CA
Canada
Prior art keywords
tumor
peptide
homing
klaklak
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002359633A
Other languages
English (en)
Inventor
H. Michael Ellerby
Dale E. Bredesen
Renata Pasqualini
Erkki I. Ruoslahti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanford Burnham Prebys Medical Discovery Institute
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2359633A1 publication Critical patent/CA2359633A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un conjugué pro-apoptotique de domiciliation renfermant une molécule de ciblage de tumeur qui cible sélectivement un type déterminé de cellule ou de tissu de mammifère lié à un peptide anti-microbien. Ce conjugué est internalisé sélectivement par ce type de cellule ou ce tissu de mammifère, à l'égard duquel il manifeste une toxicité élevée. Le peptide antimicrobien a une faible toxicité à l'égard de la cellule de mammifère lorsqu'il n'est pas lié à la molécule de ciblage de la tumeur. Le conjugué pro-apoptotique selon l'invention peut être, par exemple, CNGRC-GG-¿D?(KLAKLAK)¿2? ou ACDCRGDCFC-GG-¿D?(KLAKLAK)¿2?. Ces conjugués conviennent notamment pour le traitement d'un patient porteur d'une tumeur à vasculature angiogénique.
CA002359633A 1999-01-22 2000-01-21 Conjugues pro-apoptotiques de domiciliation et leurs methodes d'utilisation Abandoned CA2359633A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23590299A 1999-01-22 1999-01-22
US09/235,902 1999-01-22
PCT/US2000/001602 WO2000042973A2 (fr) 1999-01-22 2000-01-21 Conjugues pro-apoptotiques de domiciliation et leurs methodes d'utilisation

Publications (1)

Publication Number Publication Date
CA2359633A1 true CA2359633A1 (fr) 2000-07-27

Family

ID=22887331

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002359633A Abandoned CA2359633A1 (fr) 1999-01-22 2000-01-21 Conjugues pro-apoptotiques de domiciliation et leurs methodes d'utilisation

Country Status (5)

Country Link
EP (1) EP1150701A4 (fr)
JP (1) JP4531267B2 (fr)
AU (1) AU770381B2 (fr)
CA (1) CA2359633A1 (fr)
WO (1) WO2000042973A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003520808A (ja) * 2000-01-21 2003-07-08 ザ バーナム インスティチュート プロアポトーシス活性を有するキメラ前立腺ホーミングペプチド
AU781951B2 (en) * 2000-02-02 2005-06-23 Transgene S.A. Targeting peptides
ATE415414T1 (de) 2000-09-11 2008-12-15 Pasteur Institut Mitochondrialen membrane permeabilisierung durch hiv-1 vpr und screeningsverfahren
US20030077826A1 (en) * 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
US8507445B2 (en) 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7671010B2 (en) * 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7192921B2 (en) 2001-11-08 2007-03-20 The Burnham Institute Peptides that home to tumor lymphatic vasculature and methods of using same
WO2003040693A2 (fr) 2001-11-08 2003-05-15 The Burnham Institute Peptides visant les vaisseaux lymphatiques des tumeurs et procedes d'utilisation correspondants
EP1346729A1 (fr) * 2002-03-19 2003-09-24 Cardiovascular Research Institute Maastricht Cibler l'angiogénèse du myocarde à l'aide de CD13/APN
AU2003242506A1 (en) * 2002-07-12 2004-02-02 Novo Nordisk A/S Tf antagonist
JP4524359B2 (ja) * 2003-03-24 2010-08-18 学校法人日本医科大学 癌に特異的に作用する細胞死誘導融合遺伝子及びその遺伝子産物
GB0312309D0 (en) 2003-05-29 2003-07-02 Gaslini Children S Hospital G Targeted liposome
US7598341B2 (en) 2003-10-31 2009-10-06 Burnham Institue For Medical Research Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
WO2005094383A2 (fr) * 2004-03-31 2005-10-13 Buck Institute Peptides chasseurs-tueurs et procedes d'utilisation
WO2006029343A2 (fr) * 2004-09-07 2006-03-16 The Burnham Institute Peptides ciblant selectivement le systeme cardio-vasculaire et conjugues et procedes associes
AU2006320327A1 (en) * 2005-12-01 2007-06-07 Duke University Compounds and methods for inhibiting apoptosis
FI121959B (fi) * 2008-05-09 2011-06-30 Pirjo Laakkonen Aivokasvaimiin hakeutuva peptidi
EP2414389A1 (fr) * 2009-04-01 2012-02-08 Schmidt-Wolf, Ingo Peptides ciblant une tumeur, compositions thérapeutiques et de diagnostic comprenant les peptides
CA2795289A1 (fr) * 2010-04-08 2011-10-13 Sanford-Burnham Medical Research Institute Methodes et compositions pour une administration amelioree de composes
US10669311B2 (en) 2015-04-23 2020-06-02 Sanford Burnham Prebys Medical Discovery Institute Targeted delivery system and methods of use therefor
EP3405209B1 (fr) * 2016-01-19 2021-05-26 The University Of Western Australia Nouveaux conjugués biomoléculaires et leurs utilisations
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11021529B2 (en) 2017-03-03 2021-06-01 Massachusetts Institute Of Technology Antimicrobial constructs and uses thereof
CN108314741B (zh) * 2018-03-22 2021-08-03 中国人民解放军第四军医大学 一种肿瘤血管靶向抗癌肽nkl-dota及其制备方法
JP2023523039A (ja) * 2020-04-22 2023-06-01 オンコヴォリューション エル・エル・シー ペプチド白金錯体およびその使用方法
CN112830975B (zh) * 2021-02-02 2023-03-10 西南交通大学 α-螺旋构象稳定的促凋亡双环多肽及制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789542A (en) * 1994-04-22 1998-08-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Amphipathic peptides
US5773292A (en) * 1995-06-05 1998-06-30 Cornell University Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
ATE214075T1 (de) * 1996-05-31 2002-03-15 Health Research Inc Monoklonale antikörper gegen endoglin und ihre verwendung in der anti-angiogenese-therapie
DE69734887T2 (de) * 1996-09-10 2006-08-24 The Burnham Institute, La Jolla Tumor findende moleküle, davon abstammende konjugate und verfahren zu deren verwendung
EP1062232B1 (fr) * 1998-03-13 2008-09-10 The Burnham Institute Molecules se logeant dans divers organes ou tissus

Also Published As

Publication number Publication date
AU3348600A (en) 2000-08-07
WO2000042973A3 (fr) 2000-09-28
WO2000042973A2 (fr) 2000-07-27
JP4531267B2 (ja) 2010-08-25
EP1150701A2 (fr) 2001-11-07
EP1150701A4 (fr) 2003-03-26
AU770381B2 (en) 2004-02-19
JP2002535258A (ja) 2002-10-22

Similar Documents

Publication Publication Date Title
AU770381B2 (en) Homing pro-apoptotic conjugates and methods of using same
US20010046498A1 (en) Chimeric prostate-homing peptides with pro-apoptotic activity
US6784153B1 (en) Methods of homing molecules to lung using membrane dipeptidase
US6296832B1 (en) Molecules that home to a selected organ in vivo
US5622699A (en) Method of identifying molecules that home to a selected organ in vivo
WO2001053342A9 (fr) Peptides chimeres de ciblage de la prostate comportant une activite pro-apoptotique
US6576239B1 (en) Angiogenic homing molecules and conjugates derived therefrom
EP0987275B1 (fr) Molécules qui s'adressent in vivo vers un organe ou tissu prélevé
US6232287B1 (en) Molecules that home to various selected organs or tissues
US7488792B2 (en) Collagen-binding molecules that selectively home to tumor vasculature and methods of using same
EP0927045B1 (fr) Molecules se logeant dans une tumeur, conjugues tires de ces molecules et leurs procedes d'utilisation
DK1859041T4 (en) APROTINE POLYPEPTIDES FOR TRANSPORTING A BLOOD-BRAIN BARRIER CONNECTION
US6174687B1 (en) Methods of identifying lung homing molecules using membrane dipeptidase
US20080188421A1 (en) Hunter-Killer Peptides and Methods of Use
US6743892B1 (en) Molecules that home to a selected organ in vivo
AU728668B2 (en) Molecules that home to a selected organ or tissue in vivo and methods of identifying same

Legal Events

Date Code Title Description
FZDE Dead